炎琥宁联合阿糖腺苷治疗小儿病毒性脑炎的疗效及对T淋巴细胞的影响  

Clinical efficacy of potassium sodium pehydroandroand rographolide succinate combined with vidarabine in treatment of infants with viral encephalitis and its influence on T lymphocytes

作　　者：郭黎[1] 段武琼[1] 

机构地区：[1]陕西省安康市中心医院儿科,陕西安康725000

出　　处：《实用临床医药杂志》2016年第23期82-84,共3页Journal of Clinical Medicine in Practice

摘　　要：目的探讨炎琥宁联合阿糖腺苷治疗小儿病毒性脑炎的疗效及对T淋巴细胞的影响。方法选取95例病毒性脑炎患儿为研究对象,随机分为观察组48例和对照组47例。在常规治疗基础上,对照组采用炎琥宁治疗,观察组采用炎琥宁联合阿糖腺苷进行治疗,疗程均为7 d。比较2组临床疗效及症状改善情况;观察治疗前后T淋巴细胞亚群的变化,记录用药期间不良反应发生情况。结果治疗后,观察组总有效率为91.67%,显著高于对照组的76.60%(P<0.05);观察组退热时间、意识恢复时间、精神症状缓解时间、头痛及呕吐缓解时间均较对照组明显缩短(P<0.01);2组CD3+、CD4+、CD8+T细胞亚群细胞数均显著增加(P<0.01),观察组增加程度更为显著(P<0.01);2组不良反应比较,无显著差异(P>0.05)。结论炎琥宁联合阿糖腺苷可有效改善病毒性脑炎患儿T细胞亚群水平,提高临床疗效,且安全性高。Objective To explore the clinical efficacy of potassium sodium pehydroandroan- drographolide succinate combined with vidarabine in the treatment of infants with viral encephalitis and its influence on T lymphocytes. Methods A total of 95 infants with viral encephalitis were se- lected as study subjects, and were randomly divided into observation group （n = 48 ） and control group （n = 47）. On the basis of routine therapies, control group was added with potassium sodium pehydroandroandrographolide succinate while observation group was given potassium sodium pe- hydroandroandrographolide succinate combined with vidarabine, for totally 7 d. Clinical efficacy and improvement of clinical symptoms were compared between two groups, the changes of T lymphocyte subgroups before and after treatment were observed, and the occurrence rates of adverse reactions dur- ing drug administration were recorded. Results The total response rate was 91.67% in observation group, evidently higher than the 76.60% in control group. Observation group was markedly shorter than control group in pyretolystic time, recovery time of consciousness, alleviation time of psychologi- cal symptoms, and remission time of headache and vomiting （P 〈0.01）. CD3^＋ , CD4^＋ and CD8^＋ T cell subgroup cell count increased in both groups after treatment （P 〈 0.01 ）, which increased more significantly in observation group than that in control group （P 〈 0.01 ）. However, there was no sig- nificant difference between two groups in the total occurrence rate of adverse reactions （ P 〉 0.05 ）. Conclusion Potassium sodium pehydroandroandrographolide succinate combined with vidarabine can effectively improve the T cell subgroup level and increase the clinical efficacy with high safety in the treatment of infants with viral encephalitis.

关 键 词：炎琥宁 阿糖腺苷 病毒性脑炎 小儿 T淋巴细胞 

分 类 号：R529.3[医药卫生—内科学]